Understanding what is acetylcholine begins with its role as the main chemical messenger for daily muscle movement and internal organ control. Made inside nerve tips, this organic compound sends signals between cells to trigger muscle flexing, slow heart pace, and guide brain talk [7]. It was the first messenger found by experts, showing that nerves communicate through chemical agents instead of direct nerve contact. Today, research teams know that its networks reach into memory circuits, immune cell migration, and mental health drugs.
What Is Acetylcholine?
The direct answer to what is acetylcholine is that it acts as a chemical messenger carrying instructions between nerve cells and target tissues in the central nervous system (CNS) and peripheral pathways. Cells also call it ACh. It is an ester formed from acetic acid and choline, and the word cholinergic describes any cell or synapse that makes or responds to this compound. When motor nerves command skeletal muscles to flex, they release ACh at motor endplates to spark fast contraction [7].
Early physiological tests laid the groundwork for modern neuropharmacology. British physiologist Henry Dale documented its nervous actions during his Harvey Lecture on May 20, 1937, citing how Otto Loewi had demonstrated chemical transmission four years earlier through experiments on beating frog hearts. Their joint tests proved that nerve impulses trigger chemical release into tissues [3]. Dale confirmed that acetylcholine acts in autonomic ganglia and motor endplates, showing how one chemical produces distinct bodily actions depending on the receiving organ.
Biological research shows that ACh signaling is not restricted to animal nerves. Biologists have found enzymes for ACh synthesis, uptake, and breakdown in primitive single-celled organisms, proving that the chemical evolved long before complex animal brains appeared. For example, pathogenic amoebae in the genus Acanthamoeba produce the molecule to drive cell growth and proliferation by activating a membrane-located M1-muscarinic receptor homolog [7]. Similar non-neuronal systems exist in human endothelial cells and immune lymphocytes, where the chemical helps coordinate local cellular defenses.
Chemical Structure and Synthesis
The chemical identity of acetylcholine reflects a concise molecular architecture. According to database entries from ChEBI and ChemSpider, the systematic IUPAC name for the cation is 2-acetyloxy-N,N,N-trimethylethanaminium, also cataloged as O-acetylcholine with ChemSpider ID 182 and KEGG COMPOUND entry C01996 [1, 4, 5]. The molecule holds the formula C7H16NO2, an average mass of 146.210, a monoisotopic mass of 146.11756, and InChIKey OIPILFWXSMYKGL-UHFFFAOYSA-N [1, 4]. Metabolite profiles in both Homo sapiens (indexed under DOI 10.1038/nbt.2488) and Mus musculus confirm that it carries a permanent positive electrical charge on its quaternary nitrogen atom [1]. Because this charged ammonium head prevents the molecule from diffusing through greasy lipid membranes, circulating ACh can’t cross the blood-brain barrier under normal physiological conditions [7]. The compound stays in outer fluids unless transport proteins move it.
Neurons make ACh locally within presynaptic nerve tips instead of importing it from distant sites. Synthesis relies on choline acetyltransferase (ChAT), an enzyme that transfers an acetyl group from acetyl-CoA to free choline. Once made in the terminal cytoplasm, the neurotransmitter is loaded into round synaptic vesicles by the vesicular acetylcholine transporter, a carrier protein known as VAChT. Vesicular packaging protects the chemical from premature breakdown and concentrates thousands of units into vesicles, preparing them for calcium-dependent exocytosis whenever an impulse arrives [7].
Fast cleanup of cholinergic signals is needed for healthy nerve and muscle function. In the synaptic gap, the enzyme acetylcholinesterase (AChE) splits free ACh into inactive acetate and choline within fractions of a millisecond [7]. High-affinity choline transporters then take up the recovered choline into the neuron to reset the synapse.
Acetylcholine at the Neuromuscular Junction
The neuromuscular junction serves as the classic site for studying chemical transmission in skeletal muscle fibers, where somatic motor neurons in the spinal cord extend long axons through peripheral motor nerves to interface with the motor endplate [7]. ACh functions as the sole chemical transmitter across this junction to drive movement.
When an electrical impulse reaches the motor nerve terminal, depolarization causes voltage-gated P-type calcium channels to open, allowing calcium ions to rush inward and prompt synaptic vesicles to fuse with the presynaptic membrane. This fusion event releases roughly hundreds of thousands of acetylcholine molecules into the synaptic gap. The released transmitter diffuses across the narrow cleft to bind nicotinic ion-channel receptors clustered along the folded muscle membrane, opening pathways for sodium influx and potassium efflux that generate an endplate potential [7]. Muscle contraction follows within milliseconds.
Because muscle movement depends on precise cholinergic control, several medical disorders and toxins disrupt this junction. In myasthenia gravis, autoimmune antibodies destroy postsynaptic nicotinic receptors, causing progressive muscle weakness and fatigue during repeated activity. In Eaton-Lambert syndrome, antibodies attack presynaptic P-type calcium channels, reducing neurotransmitter release. Lethal poisons also target this junction: botulinum toxin cleaves SNARE proteins to block vesicle fusion, whereas chemical nerve agents like sarin inhibit acetylcholinesterase, trapping excess acetylcholine in the synapse until respiratory muscles fail [7].
Nicotinic Receptor Ion Channels
Nicotinic acetylcholine receptors represent the best-studied family of ionotropic receptors in human biology. Structural investigations by biophysicist N. Unwin reported in FEBS Letters showed that these receptors form pentameric complexes with a total molecular mass of 290 kilodaltons. Five individual protein subunits assemble symmetrically around a central water-filled pore that spans the cell membrane. Each subunit features four transmembrane domains with both the amino and carboxyl terminals located on the extracellular surface, placing these channels within the Cys-loop receptor family. Electron microscopy on postsynaptic membranes revealed that agonist binding triggers rotational displacements of protein chains parallel to the membrane plane, breaking apart a constricting hydrophobic gate to let ions pass through [8].
Pore opening occurs through fast shape changes when transmitter molecules occupy extracellular binding pockets. Under physiological conditions, opening the channel gate needs exactly two molecules of acetylcholine. When both sites are filled, protein shifts break open the gate, producing a central channel aperture measuring roughly 0.65 nanometers across [8]. Positively charged ions pass across the channel, with sodium entering and potassium exiting at conductances between 50 and 110 picosiemens. The channel opens in less than a millisecond before the ligand diffuses away.
Vertebrate tissues express muscle and neuronal receptor subtypes. Muscle-type receptors at the neuromuscular junction use an adult combination of (α1)2β1δε subunits and are blocked by the plant poison curare [8]. Neuronal subtypes combine subunits like α2 through α10 and β2 through β4, forming diverse pentamers that hexamethonium selectively blocks. Curare spares neuronal sites.

Muscarinic G-Protein Receptors
Muscarinic acetylcholine receptors operate through slower metabotropic mechanisms that alter target cells over seconds or minutes. Named after muscarine, a compound isolated from the poisonous mushroom Amanita muscaria, these proteins belong to the G-protein-coupled receptor family [9]. Ligand binding activates intracellular G proteins, launching biochemical cascades that modulate cell excitability across internal organs.
Pharmacological research has characterized five distinct muscarinic receptor subtypes, labeled M1 through M5 [9]. Subtypes M1, M3, and M5 couple to Gq proteins, activating phospholipase C to raise intracellular levels of inositol trisphosphate and calcium ions, generating predominantly excitatory responses in target tissues. By contrast, M2 and M4 subtypes couple to Gi/Go proteins, inhibiting adenylate cyclase to lower cyclic AMP levels and producing inhibitory outcomes [7]. In autonomic ganglia, nicotinic receptors drive initial fast depolarization, but muscarinic M2 and M1 receptors mediate subsequent hyperpolarization and slow depolarization during cellular recovery. Selective antagonist drugs like pirenzepine bind with higher potency to M1 receptors than to other subtypes, allowing researchers to isolate individual receptor actions.
Muscarinic receptors mediate the primary effects of the parasympathetic nervous system. Postganglionic parasympathetic fibers release acetylcholine directly onto target tissues, slowing cardiac pacemaking, constricting airways, and stimulating digestive secretions. The sympathetic division also uses muscarinic receptors in select locations: sympathetic fibers innervating sweat glands release acetylcholine instead of noradrenaline to regulate body temperature [7]. In the circulatory system, serum acetylcholine binds endothelial muscarinic receptors to stimulate nitric oxide synthesis, which prompts vascular smooth muscle relaxation and leads to vessel dilation.
How Acetylcholine Regulates Brain Networks
In the central nervous system, acetylcholine functions as a neuromodulator that coordinates attention, cortical arousal, and sleep-wake transitions. Central cholinergic innervation arises from two main anatomical systems located deep in the brain. The first network sits in the basal forebrain, where the nucleus basalis of Meynert and the medial septal nucleus send broad projections to the neocortex and hippocampus [7]. Ascending projections release acetylcholine to sharpen signal processing during demanding tasks and strengthen synaptic plasticity during waking hours. Degeneration of this forebrain pathway correlates directly with cognitive decline in neurodegenerative illness.
The second cholinergic hub sits in the upper brainstem within the pontomesencephalotegmental complex. The network includes the pedunculopontine nucleus and laterodorsal tegmental nucleus, projecting to the thalamus and basal ganglia [7]. High brainstem cholinergic activity promotes rapid eye movement (REM) sleep, while low tone permits restorative non-REM sleep.
In the striatum, large cholinergic interneurons modulate motor control without extending fibers outside the basal ganglia, synchronizing their firing pauses with dopamine bursts from the substantia nigra when animals detect salient sensory cues [7]. Optogenetic research by Saunders and colleagues showed that forebrain cholinergic neurons can corelease both acetylcholine and GABA onto target interneurons. Anatomical studies confirmed that these cholinergic cells express the GABA-synthesizing enzyme Gad2 and the vesicular GABA transporter Slc32a1 [6]. Dual release indicates that cholinergic neurons use fast GABAergic inhibition with slower cholinergic neuromodulation, expanding the computational capacity of forebrain circuits.
Learning and Memory Systems
The connection between acetylcholine and memory formation is a cornerstone of modern cognitive neuroscience. Cholinergic projections reaching the hippocampus and cerebral cortex facilitate synaptic plasticity, helping neural circuits register new sensory experiences without erasing previously established memories. In animal models, experimental disruption of acetylcholine delivery to the neocortex impairs performance on simple discrimination tasks, mirroring factual learning deficits in clinical patients [7]. When lesions block cholinergic input to the hippocampus, subjects develop severe forgetfulness comparable to anterograde amnesia. Adequate cholinergic transmission is needed for encoding fresh knowledge into long-term biological storage. Without sufficient acetylcholine, cortical circuits can’t consolidate incoming information into stable synaptic patterns.
Pharmacological studies show how muscarinic antagonism impairs learning, as volunteers given scopolamine, a muscarinic antagonist that readily penetrates the central nervous system, temporarily lose the ability to acquire new memories. The compound selectively inhibits M1 muscarinic receptors in cortical networks, producing amnesia, confusion, and hallucinations. Medical literature through 2016 identified the M1 subtype as the sole muscarinic receptor tied to drug-induced delirium [7]. The selective action explains why antimuscarinic medications pose distinct cognitive hazards in vulnerable individuals.
Recent research demonstrates that acetylcholine plays a bidirectional role in learning, where adequate cholinergic tone supports active encoding during wakefulness but excess acetylcholine impairs memory consolidation during sleep [7]. Elevated cholinergic tone during rest disrupts verbal recall in early Alzheimer’s disease and mild cognitive impairment.
Anticholinergic Burden in Clinical Care
Prescribing drugs that block acetylcholine poses serious risks for older adults. In a clinical study published in the Journal of the American Geriatrics Society, a research team led by Dr Chris Fox at the University of East Anglia evaluated 13,000 patients aged 65 and older [6]. Scientists found that roughly half of older people were taking such drugs. NHS pharmacist Ian Maidment warned that use of these medicines has risen as more illnesses are treated.
Scientists rated eighty common medicines on a scale from one for mild effects up to three for severe activity to assess cumulative exposure. During the 1991 to 1993 tracking window, mortality reached 20% among individuals scoring four or higher on the drug scale, whereas only 7% of unexposed patients died. Scores of five or higher brought a 4% drop in brain function ratings, which Dr Susanne Sorensen from the Alzheimer’s Society said can push fragile people into confusion. Aricept is given to Alzheimer’s patients to raise ACh levels. Dr Clare Gerada of the Royal College of GPs advised talking with doctors before stopping medicines, while Rebecca Wood of Alzheimer’s Research UK said the data show the need for careful prescribing [6].
While blocking receptors harms patients, targeted activation opens new therapeutic options. On October 2, 2024, the FDA approved KarXT (Cobenfy), from Karuna and Bristol Myers Squibb, for schizophrenia. Katie Kingwell reported in Nature Reviews Drug Discovery that the oral drug combines xanomeline, a dual M1 and M4 agonist, with trospium, an antagonist that curbs peripheral side effects. By targeting muscarinic sites instead of dopamine, Cobenfy provides the first new mechanism for schizophrenia in over 70 years [2].
- DICTIONARY ENTRY European Bioinformatics Institute. (2017). Acetylcholine (CHEBI:15355). ChEBI. [Article Link]
- ONLINE NEWS Kingwell, K. (2024). FDA approves first schizophrenia drug with new mechanism of action since 1950s. Nature Reviews Drug Discovery, 23(11), 803. [Article Link]
- WEBSITE Google Scholar. (2016). Scholarly articles for acetylcholine. Google Scholar. [Article Link]
- WEBSITE Royal Society of Chemistry. (2026). O-Acetylcholine (ChemSpider ID 182). ChemSpider. [Article Link]
- WEBSITE Kyoto Encyclopedia of Genes and Genomes. (n.d.). KEGG COMPOUND: C01996 (Acetylcholine). KEGG. [Article Link]
- ONLINE NEWS Gallagher, J. (2011). Warning over combining common medicines for elderly. BBC News. [Article Link]
- WEBSITE Wikipedia contributors. (n.d.). Acetylcholine. Wikipedia, The Free Encyclopedia. [Article Link]
- WEBSITE Wikipedia contributors. (n.d.). Nicotinic acetylcholine receptor. Wikipedia, The Free Encyclopedia. [Article Link]
- WEBSITE Wikipedia contributors. (n.d.). Muscarinic acetylcholine receptor. Wikipedia, The Free Encyclopedia. [Article Link]
Cover image: CCoil / Wikimedia Commons, CC BY-SA 3.0